The Advancement of Clinical Practice in Chronic Kidney Disease

From a CME Symposium held on March 22, 2002 at the Renal Physicians Association (RPA) Annual Meeting in Washington, DC.
This symposium was approved by the RPA. It was not part of the official RPA Annual Meeting as planned by the RPA Program Committee.
Access to this program is free but HDCN free zone registration is required.
Welcome and Introductory Remarks
Anton Schoolwerth, M.D., M.S.H.A. and W. Kline Bolton, M.D. (Co-moderators)
The Definition and Prevalence of CKD
William McClellan, M.D., M.P.H.
The Interrelationship Between Cardiovascular Disease and CKD
Patrick Parfrey, M.D.
Anemia in Patients With Cardiovascular Disease and Concomitant Renal Insufficiency
Amin Al-Ahmad, M.D.
Correcting Anemia: Improving Renal and Cardiovascular Outcomes
Ajay K. Singh, M.D., M.B.A. Presented by: Donal Reddan, M.B., M.H.S.
Panel Discussion
Speakers and Moderators
Concluding Remarks and Program Evaluation
Anton Schoolwerth, M.D., M.S.H.A.

At the completion of this program, participants should be able to:

Discuss the increased prevalence of chronic kidney disease in the United States;
Define chronic kidney disease using the stratification guidelines of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI);
Describe the need for earlier identification of and interventions for chronic kidney disease in the United States;
Describe the burden of chronic kidney disease in patients with cardiovascular complications, and;
Discuss how anemia is managed in patients with chronic kidney disease and cardiovascular disease.

W. Kline Bolton, M.D. (Co-moderator)
Professor of Internal Medicine
Division Head, Division of Nephrology
University of Virginia
Charlottesville, VA

Anton Schoolwerth, M.D., M.S.H.A. (Co-moderator)
Chair, Nephrology
Department of Internal Medicine, Nephrology
Medical College of Virginia Campus
Virginia Commonwealth University
Richmond, VA

William McClellan, M.D., M.P.H.
Clinical Professor
Department of Medicine
Emory University School of Medicine
Medical Director
Health Services Research
Georgia Medical Care Foundation Atlanta, GA

Patrick Parfrey, M.D.
University Research Professor
Division of Nephrology
The Health Sciences Centre Memorial University Newfoundland
St. John's, Newfoundland, Canada

Amin Al-Ahmad, M.D.
Instructor in Medicine
Department of Medicine, Cardiology
Tufts University School of Medicine
Boston, MA

Donal Reddan, M.B., M.H.S.
Associate in Medicine
Department of Nephrology
Department of Medicine
Duke University Medical Center
Durham, NC

CME
CEU

The post-test and evaluation form are at this link, but you must listen to all talks from this symposium prior to completing the test.
CME: The Oxford Institute for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (AACME) to provide continuing medical education for physicians.
The Oxford Institute for Continuing Education designates this educational activity for up to 2.0 hours in category 1 credit towards the AMA Physician's Recognition Award. Each physician should claim only those hours of credit actually spent in the educational activity.

CEU: These talks are also designated to provide 2.0 hours of CEU nursing education credits, sponsored by the Renal Education Association. The Renal Education Association is accredited by the State of California Board of Nursing to provide continuing education for nurses (provider number: CEP 13092).

Posting date: July 3, 2002
Review date: July 3, 2003

INSTRUCTIONS FOR CREDIT:
Participation in this self-study activity should be completed in approximately two (2.0) hours. There are no fees for participating and receiving CME or CEU credit for this activity. To successfully complete this activity and receive credit, participants must follow these steps during the period of July 3, 2002 through July 3, 2003.
1. Register for continuing education credit by completing the registration process.
2. Read the goals and learning objectives.
3. Read the article text and tables, and review figures.
4. Read, complete, and submit answers to the post-test questions and evaluation questions. You must receive a test score of at least 75% and respond to all evaluation questions to receive your online CME or CEU certificate.
TARGET AUDIENCE:
This activity is designed for renal physicians and other healthcare professionals who treat and manage patients with chronic kidney disease.

FACULTY DISCLOSURE STATEMENTS:
All faculty participating in continuing medical education programs are expected to disclose to the program audience any real or apparent conflicts of interest related to the subject under discussion. The faculty disclosure information is as follows:
Al-Ahmad: no real or apparent conflicts of interest to disclose.
Bolton: grant and/or research support from Ortho Biotech Products, L.P., Amgen Inc., and Merck & Co. He is also a consultant for Ortho Biotech Products, L.P., Alteon, Amgen Inc., and Baxter Healthcare Corporation.
McClellan: consultant for Ortho Biotech Products, L.P.
 Parfrey: grant and/or research support from Johnson & Johnson Pharmaceutical Research & Development, L.L.C. He is also a consultant for Johnson & Johnson, Ortho Biotech Products, L.P., Amgen Inc., and Roche.
 Reddan: Other financial or material support: Ortho Biotech Products, L.P., Early Renal Insufficiency Advisory Group
 Schoolwerth: grant and/or research support from, is a consultant for, and is a member of the Speakers Bureau for Ortho Biotech Products, L.P.
DISCLOSURE OF UNLABELED USE:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Oxford Institute for Continuing Education, ASN, HDCN, and the Renal Education Association do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRODUCT DISCLOSURE STATEMENT:
Generic/Common name: Recombinant human erythropoietin (r-HuEPO; epoetin alfa).
Trade name: Procrit® or Epogen®
Approved use: Treatment of anemia in chronic renal failure; in zidovudine-treated HIV-infected patients; and in cancer patients on chemotherapy. Reduction of allogeneic blood transfusion in surgery patients
Unapproved/investigational use: Anemia in patients with congestive heart failure and the chronically critically ill.

This educational activity is supported by an educational grant from Ortho Biotech Products, L.P.
This activity has been planned and produced in accordance with the ACCME Essential Areas and Policies and with CE policies of the State of California Board of Registered Nursing.
From a CME Symposium held on March 22, 2002 at the Renal Physicians Association (RPA) Annual Meeting in Washington, DC. This symposium was approved by the RPA. It was not part of the official RPA Annual Meeting as planned by the RPA Program Committee.
BACK TO
TOPIC INDEX :